Breast cancer: HER2--a good addiction

Nat Rev Clin Oncol. 2012 Mar 13;9(4):196-7. doi: 10.1038/nrclinonc.2012.36.


Recent neoadjuvant studies have examined the effects of adding single or dual agents targeting HER2 to chemotherapy, finding unanimously that dual HER2 targeting markedly improves pathologic response. These findings have significant implications for future trial designs, particularly if the impact on pathologic response is accompanied by improved disease-free survival or overall survival.

Publication types

  • News

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Clinical Trials as Topic
  • Female
  • Humans
  • Prognosis
  • Receptor, ErbB-2 / metabolism*


  • Receptor, ErbB-2